Instead of importing foreign price controls and restricted access policies, Congress should work to lower out-of-pocket costs so that patients can afford the treatments they need and preserve incentives for innovation
New Members and Representation from Amgen, Ardelyx, Boehringer Ingelheim, Cortexyme, DuPont Nutrition & Biosciences, Ernst & Young, GRAIL, Medtronic, Nkarta Therapeutics
CLSA to Host Leaders of BIO, PhRMA, AdvaMed & Johnson & Johnson Innovation | JLABS for Discussion on Life Sciences Leadership, Policy & Direction
California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, issued the following statement in response to the Trump Administration’s drug importation proposal unveiled today.
Today, CLSA announced a new life sciences credit card member benefit through its partnership with Brex, the corporate card built for the life sciences that accelerates entrepreneurs and scaling businesses.
Today, CLSA issued a statement applauding the Congressional passage of S. 1379, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019, legislation that is key to strengthening our national preparedness and response for public health emergencies and accelerating medical countermeasure research and development. Share links below and more information attached.
Today, CLSA announced the transitional board appointment of Melinda Richter, Global Head, Johnson & Johnson Innovation – JLABS from Vice Chair to Chair of CLSA’s Board of Directors. Alex Kelly, Executive Vice President, Corporate Affairs and Chief Communications Officer, Allergan, will move into the position of Vice Chair, ceding the role of Treasurer to Jeff Jonker, President and CEO, Ambys Medicines.
CLSA today announced the appointment of Molly Fishman as Director of Federal Government Relations based in CLSA’s Washington, D.C. Office. Fishman joins CLSA following many years on Capitol Hill, where she most recently served as Legislative Director for U.S. Representative Jackie Speier.
California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, joined with Congressman Scott Peters (D-San Diego) to issue the following statements announcing support for the reintroduction of the Protect Medical Innovation Act of 2019, bipartisan legislation that fully repeals the 2.3% excise tax levied on medical device firms as part of the Affordable Care Act.
CLSA today announced the appointment of Andrew Setikas as Senior Vice President of Business Development and Strategy starting March 25, 2019. The addition of Setikas to CLSA’s senior leadership team marks the continued expansion and rapid growth of CLSA, which advances California’s world-leading life sciences sector by advocating for effective national, state and local public policies and supporting entrepreneurs and life sciences businesses.